Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00074854
Status:
COMPLETED
Last Update Posted:
2006-11-09
First Post:
2003-12-22
Brief Title:
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy Paclitaxel And Carboplatin Vs Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether CP-547632 an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy carboplatin and paclitaxel is effective in the treatment of advanced stage non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None